Hybio Pharmaceutical Co., Ltd. (SZSE: 300199)
Health Care · Pharmaceuticals · CN
CN¥23.10
-10.67% today · -20.2% 1Y
Hybio Pharmaceutical Co., Ltd. (SZSE: 300199) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.04B and employs 1,226 people.
Over the last twelve months the share price has lost 20.2%, trading between 16.23 and 30.03.
Tweenvest scores Hybio Pharmaceutical Co., Ltd. across four factors: quality 46/100, value 17/100, growth 61/100. Its strongest factor is growth.
300199 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.04B
- Revenue (TTM)
- $162.70M
- P/E
- 162.31
- EPS
- 0.14
- Dividend yield
- —
- Beta (5Y)
- 0.71
- 52-week high
- CN¥30.03
- 52-week low
- CN¥16.23
- Avg volume (3M)
- —
- Shares outstanding
- 883.24M
- Employees
- 1,226
- Next earnings
- —
About Hybio Pharmaceutical Co., Ltd.
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
- ISIN
- CNE1000011T7
- Founded
- 1998
- Listed since
- Apr 7, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.38 | +0.54% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.